Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome - 26/02/23
, Miguel González-Andrades b, c, d, ⁎ Abstract |
Purpose |
To evaluate long-term visual and anatomical outcomes in neovascular age-related macular degeneration (nAMD) patients treated with anti-vascular endothelial growth factor (VEGF) agents depending on the time delay from confirmed diagnosis to treatment initiation.
Materials and methods |
Seventy-three nAMD patients (73 eyes) treated with anti-VEGF agents for 12 months using the pro re nata regimen were included in this retrospective longitudinal study. Patients were split into 3 groups according to the time from diagnosis to first anti-VEGF injection: < 48 h (group 1); 48 h-7 days (group 2); > 7 days (group 3). Decimal best-corrected visual acuity (VA) and macular thickness (MT) were recorded at baseline and 1–2-, 3–4-, 6- and 12-month later. Furthermore, age, gender as well as the applied treatment and number of injections after 12 months of treatment were also registered and compared.
Results |
Long-term effect of the treatment demonstrated enhanced VA in group 1 patients compared with the rest of groups after 1–2-, 6-, and 12-month follow-up (P < 0.05). Positive effects of early treatment were additionally corroborated by the augmented percentage of patients with normal VA in the group 1 respect to the rest of groups over studied time points (P < 0.05). Moreover, the VA gain in nAMD at group 1 was obtained with a mean of 3.7 intravitreal injections over 1-year follow-up period. Regarding MT, non-significant difference was observed among groups.
Conclusions |
An early initial treatment with VEGF inhibitors is critical to achieve the best functional benefits of this therapy in new-onset nAMD patients.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Anti-VEGF therapy within 48 h from diagnosis leads to long-term visual gain in nAMD. |
• | Visual gain is achieved with low IV injection number if early treatment is applied. |
• | A prompt first anti-VEGF injection promotes long-term anatomical benefits in nAMD. |
Abbreviations : AMD, MT, nAMD, OCT, SD, VA, VEGF
Keywords : Neovascular age-related macular degeneration, Visual acuity, Macular thickness, Intravitreal injections, Anti-vascular endothelial growth factor therapy
Plan
Vol 160
Article 114368- avril 2023 Retour au numéro
Article précédent
- Isoaaptamine increases ROS levels causing autophagy and mitochondria-mediated apoptosis in glioblastoma multiforme cells
- Zhi-Hong Wen, Hsiao-Mei Kuo, Po-Chang Shih, Ling-Chen Hsu, Jimmy Ming-Jung Chuang, Nan-Fu Chen, Hsi-Wen Sun, Hsin-Tzu Liu, Chun-Sung Sung, Wu-Fu Chen
- Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale
- Bram C. Agema, Sanne M. Buijs, Sebastiaan D.T. Sassen, Thomas E. Mürdter, Matthias Schwab, Birgit C.P. Koch, Agnes Jager, Ron H.N. van Schaik, Ron H.J. Mathijssen, Stijn L.W. Koolen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?